catastrophic antiphospholipid syndrome , CAPS (Abkürzung)
Asherson's syndrome

Catastrophic antiphospholipid syndrome (CAPS)

Catastrophic antiphospholipid syndrome (CAPS) is a rare condition in which blood clots form in multiple organs simultaneously, possibly leading to multi-organ system failure and death.

Catastrophic antiphospholipid syndrome, CAPS, also known as Asherson's syndrome, is an acute and complex biological process that leads to occlusion of small vessels of various organs.

In rare cases, APS leads to rapid organ failure due to generalised thrombosis; this is termed "catastrophic antiphospholipid syndrome" (CAPS) and is associated with a high risk of death.

Catastrophic Antiphospholipid Syndrome None Asherson's syndrome is an extremely rare autoimmune disorder characterized by the development, over a period of hours, days or weeks, of rapidly progressive blood clots affecting multiple organ systems of the body.

The exact cause of Asherson's syndrome is unknown.

Asherson's syndrome can rapidly result in life-threatening multiorgan failure.

Asherson's syndrome may occur in individuals who have primary or secondary APS or in individuals with lupus or other autoimmune disorders.

Catastrophic antiphospholipid syndrome, CAPS, also known as Asherson's syndrome, is an acute and complex biological process that leads to occlusion of small vessels of various organs.

In APS and Asherson's syndrome, antibodies mistakenly attack certain proteins that bind to phospholipids, which are fat molecules that are involved in the proper function of cell membranes.

Asherson's syndrome is a severe variant of antiphospholipid syndrome (APS), an autoimmune disorder in which blood clots occur in relation to the presence of antiphospholipid antibodies in the body.

Catastrophic Antiphospholipid Syndrome None Asherson's syndrome is an extremely rare autoimmune disorder characterized by the development, over a period of hours, days or weeks, of rapidly progressive blood clots affecting multiple organ systems of the body.